Johnson & Johnson (J&J) recently announced it has entered into a definitive agreement to acquire Atraverse Medical—a company attempting to pioneer next-generation left-heart access and radiofrequency (RF) technologies. Achieving safe and precise access to the left atrium remains “one of the most critical steps” in atrial fibrillation (AF) ablation, as noted in a J&J press release. Atraverse’s Hotwire transseptal access system—already used in nea…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.